Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 3, 2012, Pages 95-102

  Bishop, Jeffrey R ^a   Rubin, Leah H ^b   Reilly, James L ^b   Pavuluri, Mani N ^c   Sweeney, John A ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

antipsychotic; bone; prolactin; psychosis; risperidone

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ESTRADIOL; OSTEOCALCIN; PROLACTIN; RISPERIDONE; TESTOSTERONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BONE TURNOVER; CLINICAL ARTICLE; DSM-IV; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR DEPRESSION; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

EID: 84998179969     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312442080     Document Type: Article

References (30)

1. Abraham G. Halbreich U. Friedman R.H. Josiassen R.C. (2003a) Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 59: 17–18.
2. Abraham G. Paing W.W. Kaminski J. Joseph A. Kohegyi E. Josiassen R.C. (2003b) Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 160: 1618–1620.
3. Baastrup P.C. Christiansen C. Transbol I. (1980) Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 6: 56–59.
4. Bartke A. Matt K.S. Steger R.W. Clayton R.N. Chandrashekar V. Smith M.S. (1987) Role of prolactin in the regulation of sensitivity of the hypothalamic-pituitary system to steroid feedback. Adv Exp Med Biol 219: 153–175.
5. Bhasin S. Swerdloff R.S. (1985) Hypothalamic hypogonadism. Spec Top Endocrinol Metab 7: 237–266.
6. Coss D. Yang L. Kuo C.B. Xu X. Luben R.A. Walker A.M. (2000) Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279: E1216–E1225.
7. First M. Spitzer R.L. Gibbon M. Williams J.B.W. (1995) Structured Clinical Interview for DSM-IV Axis-I Disorders, Patient Edition (SCID-P). New York: New York State Psychiatric Institute.
8. Fitzgerald P. Dinan T.G. (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22: 12–19.
9. Haddad P.M. Wieck A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291–2314.
10. Halbreich U. Palter S. (1996) Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 22: 447–454.
11. Halbreich U. Rojansky N. Palter S. Hreshchyshyn M. Kreeger J. Bakhai Y. et al. (1995) Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57: 485–491.
12. Howes O.D. Wheeler M.J. Meaney A.M. O’Keane V. Fogelman I. Blake G. et al. (2005) Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol 25: 259–261.
13. Huber T.J. Tettenborn C. Leifke E. Emrich H.M. (2005) Sex hormones in psychotic men. Psychoneuroendocrinology 30: 111–114.
14. Kinon B.J. Gilmore J.A. Liu H. Halbreich U.M. (2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28 (Suppl. 2): 69–82.
15. Kishimoto T. Watanabe K. Shimada N. Makita K. Yagi G. Kashima H. (2008) Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 69: 385–391.
16. Krishnamra N. Seemoung J. (1996) Effects of acute and long-term administration of prolactin on bone 45ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol 74: 1157–1165.
17. Kunimatsu T. Kimura J. Funabashi H. Inoue T. Seki T. (2010) The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol 58: 360–368.
18. Manolagas S.C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115–137.
19. Meaney A.M. O’Keane V. (2007) Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 93: 136–143.
20. Meaney A.M. Smith S. Howes O.D. O’Brien M. Murray R.M. O’Keane V. (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503–508.
21. O’Keane V. (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 22: 70–75.
22. O’Keane V. Meaney A.M. (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25: 26–31.
23. Overall J.E. Gorham D.R. (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 799–812.
24. Sackett G. Unis A. Crouthamel B. (2010) Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques. J Child Adolesc Psychopharmacol 20: 489–493.
25. Seriwatanachai D. Charoenphandhu N. Suthiphongchai T. Krishnamra N. (2008) Prolactin decreases the expression ratio of receptor activator of nuclear factor kappab ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int 32: 1126–1135.
26. Seriwatanachai D. Krishnamra N. Van Leeuwen J.P. (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107: 677–685.
27. Seriwatanachai D. Thongchote K. Charoenphandhu N. Pandaranandaka J. Tudpor K. Teerapornpuntakit J. et al. (2008) Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappab ligand/osteoprotegerin ratio. Bone 42: 535–546.
28. Shibli-Rahhal A. Schlechte J. (2009) The effects of hyperprolactinemia on bone and fat. Pituitary 12: 96–104.
29. Smith S. Wheeler M.J. Murray R. O’Keane V. (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic–pituitary–gonadal axis. J Clin Psychopharmacol 22: 109–114.
30. Tresguerres J.A. Esquifino A.I. Perez Mendez L.F. Lopez-Calderon A. (1981) Possible role of prolactin in the inhibitory effect of estradiol on the hypothalamic–pituitary–testicular axis in the rat. Endocrinology 108: 83–87.